Cariprazine

CHEMBL2028019 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

427.4 g/mol

LogP

4.3

Phase

4

An atypical antipsychotic that acts as a partial agonist at dopamine D2 and D3 receptors as well as serotonin 5-HT1A receptors. It is approved for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. Its relatively high affinity for D3 receptors is thought to contribute to its effects on mood and cognition.

Moleküler Ağırlık

427,4000 g/mol

LogP

4,30

TPSA

38,80 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Stroke Major Depressive Disorder

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1

InChI

InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-

Molecular Formula

C21H32Cl2N4O

HBD / HBA

1 / 3

Döndürülebilir Bağlar

5

Ağır Atomlar

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An atypical antipsychotic that acts as a partial agonist at dopamine D2 and D3 receptors as well as serotonin 5-HT1A receptors. It is approved for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. Its relatively high affinity for D3 receptors is thought to contribute to its effects on mood and cognition.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Cariprazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2028019. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11154555. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Cariprazine PillFYI'da

Yapı

Hızlı Veriler

Formül: C21H32Cl2N4O
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.